Yield loss during optimization during pilot scale – process robustness improvement framework
Detecting yield loss at pilot scale can often be subtle yet critical. Symptoms may manifest as:Click to read the full article.
Tips for Process Development
CPPs not well defined during lifecycle optimization – ICH Q8/Q11 alignment strategy
Aligning Critical Process Parameters During Lifecycle Optimization in Pharma In the fast-paced world of pharmaceutical manufacturing, failure to clearly define Critical Process Parameters (CPPs) during lifecycle optimization can lead to…
CPPs not well defined during regulatory submission – regulatory scrutiny risk
Recognizing symptoms of poorly defined CPPs is vital for timely remediation. Here are observable indicators that may suggest a lack of clarity in CPP definitions:Click to read the full article.
CPPs not well defined during development studies – ICH Q8/Q11 alignment strategy
Identifying signals of inadequately defined CPPs early in the development phase is crucial to minimizing risk. Symptoms may manifest in various stages of production and analytical testing:Click to read the…
Control strategy inadequate during development studies – regulatory scrutiny risk
Recognizing the early signs of an inadequate control strategy is critical in preventing more significant complications. Key symptoms may include:Click to read the full article.
Control strategy inadequate during pilot scale – regulatory scrutiny risk
Recognizing the signs of inadequate control strategies at the pilot scale is key to mitigating potential risks. Symptoms can include:Click to read the full article.
Process variability exceeds limits during pilot scale – regulatory scrutiny risk
Recognizing the symptoms of process variability is crucial for timely intervention. Key signals may include:Click to read the full article.
Process not transferable during pilot scale – data expectations for filings
Identifying early symptoms signaling that the process is not transferable is critical. Common indicators include:Click to read the full article.
Process not transferable during validation planning – data expectations for filings
Identifying warning signs during the manufacturing process is essential for early intervention. Symptoms indicating that a process is not transferable during validation planning may include:Click to read the full article.
Control strategy inadequate during development studies – ICH Q8/Q11 alignment strategy
Identifying early signs of inadequate control strategies is crucial for timely intervention. Below are key symptoms and signals to watch for:Click to read the full article.
Control strategy inadequate during pilot scale – ICH Q8/Q11 alignment strategy
Identifying symptoms early can help in mitigating risks associated with inadequate control strategies. Look out for the following signals:Click to read the full article.
Process variability exceeds limits during regulatory submission – process robustness improvement framework
Recognizing symptoms of process variability early can prevent a minor issue from escalating into a significant setback during regulatory submissions. Common indicators include:Click to read the full article.